Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

May 2, 2022 | Press Releases

MARLBOROUGH, Mass., May 2, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced...

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

Apr 26, 2022 | Press Releases

MARLBOROUGH, Mass., April 26, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced...

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer

Apr 18, 2022 | Press Releases

MARLBOROUGH, Mass., April 18, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022

Apr 8, 2022 | Press Releases

MARLBOROUGH, Mass., April 8, 2022 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

Mar 22, 2022 | Press Releases

Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass., March 22, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next...